Protalix BioTherapeutics, Inc. (PLX)

Market Cap	263.92M +49.1%
Revenue (ttm)	84.69M +37.0%
Net Income	20.55M +281.0%
EPS	0.25 +256.6%
Shares Out	84.32M
PE Ratio	12.71
Forward PE	52.17
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,092,809
Open	2.860
Previous Close	2.860
Day's Range	2.825 - 3.140
52-Week Range	1.650 - 3.190
Beta	-0.02
Analysts	n/a
Price Target	11.00 (+251.44%)
Earnings Date	Nov 10, 2026

About PLX

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 15, 1998
• Employees: 226
• Stock Exchange: NYSE American
• Ticker Symbol: PLX
• Website: https://www.protalix.com

Analyst Summary

The average 12-month stock price target for PLX is $11.0, which is an increase of 251.44% from the latest price.

Price Target

$11.0

(251.44% upside)

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Nov 12, 2026

Data Sources Report a data error